Rashdan S, Minna JD, Gerber DE. Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med. 2018;6:472-478.
Brahmer JR, Lacchetti C, Thompson JA. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline summary. J Clin Oncol. 2018;14:247-249.
Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35:709-717.
Nishino M, Chambers ES, Chong CR, et al. Anti–PD-1 inhibitor–related pneumonitis in non–small cell lung cancer. Cancer Immunol Res. 2016;4:289-293. 4
Ma K, Lu Y, Jiang S, et al. The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis. Front Pharmacol. 2018;9.
Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest. 2017;152:271-281.
Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor–related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2:1607-1616.
Zhang B, Wu Q, Zhou YL, et al. Immune-related adverse events from combination immunotherapy in cancer patients: a comprehensive meta-analysis of randomized controlled trials. Int Immunopharmacol. 2018;63:292-298.
Chuzi S, Tavora F, Cruz M, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res. 2017;9:207-213.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) in partnership with the American Society of Clinical Oncology (ASCO). Management of immunotherapy-related toxicities, v. 1.2019. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. Updated November 14, 2018. Accessed March 12, 2019
Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor–related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22:6051-6060.
Lemiale V, Meert A-P, Vincent F, et al. Severe toxicity from checkpoint protein inhibitors: what intensive care physicians need to know? Ann Intensive Care. 2019;9:25.
Suresh K, Naidoo J, Lin CT, et al. Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities. Chest. 2018;154:1416-1423.
Wang GX, Kurra V, Gainor JF, et al. Immune checkpoint inhibitor cancer therapy: spectrum of imaging findings. RadioGraphics. 2017;37:2132-2144.
Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119-iv142.
Wang DY, Salem J-E, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysisfatal toxic effects associated with immune checkpoint inhibitorsfatal toxic effects associated with immune checkpoint inhibitors. JAMA Oncology. 2018;4:1721-1728.
Yamaguchi T, Shimizu J, Hasegawa T, et al. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a retrospective analysis. Lung Cancer. 2018;125:212-217.
Powell CA. Pulmonary infiltrates in a patient with advanced melanoma. J Clin Oncol. 2017;35:705-708.
Nishino M, Hatabu H, Hodi FS, et al. Drug-related pneumonitis in the era of precision cancer therapy. JCO Precis Oncol. 2017;1:1-12.
Akella P, Loganathan S, Jindal V, et al. Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - a review with case series. Respir Med Case Rep. 2019;26:17-22.
O'Kane GM, Labbé C, Doherty MK, et al. Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer. Oncologist. 2017;22:70-80.
Widmann G, Nguyen VA, Plaickner J, et al. Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy. Curr Radiol Rep. 2017;5:59-59.
Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5:95.
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158-168.
Broersen LHA, Dekkers OM, Pereira AM, et al. Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100:2171-2180.
Seto T, Sam D, Pan M. Mechanisms of primary and secondary resistance to immune checkpoint inhibitors in cancer. Med Sci (Basel). 2019;7.
Fucà G, Galli G, Poggi M, et al. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open. 2019;4:e000457.
Leighl N, Gandhi L, Hellmann M. Pembrolizumab for NSCLC: immune-mediated adverse events and corticosteroid use. J Thorac Oncol. 2015;10:S233.
Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35:785-792.
Horvat TZ, Adel NG, Dang T-O, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33:3193-3198.
Garant A, Guilbault C, Ekmekjian T, et al. Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review. Crit Rev Oncol Hematol. 2017;120:86-92.
Montani D, Seferian A, Parent F, et al. Immune checkpoint inhibitor-associated interstitial lung diseases: some progress but still many issues. Eur Respir J. 2017;50:1701319.
Scott SC, Pennell NA. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol. 2018;13:1771-1775.
Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non–small-cell lung cancer. J Clin Oncol. 2018;36:2872-2878.
Mark NM, Kargl J, Busch SE, et al. Chronic obstructive pulmonary disease alters immune cell composition and immune checkpoint inhibitor efficacy in non-small cell lung cancer. Am J Respir Crit Care Med. 2018;197:325-336.
Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
Naidoo J, Cappelli L, Lipson EJ, et al. A multidisciplinary toxicity team for cancer immunotherapy-related adverse events. J Clin Oncol. 2018;36:6538-6538.
Cui P, Liu Z, Wang G, et al. Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: a case-control study. Cancer Med. 2018;7:4115-4120.
Cho JY, Kim J, Lee JS, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. Lung Cancer. 2018;125:150-156.
Owen DH, Wei L, Bertino EM, et al. Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer. Clin Lung Cancer. 2018;19:e893-e900.
Remon J, Mezquita L, Corral Js, et al. Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. J Thorac Dis. 2018:S1516-S1533.
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342-2350.
Ahn MJ, Yang J, Yu H, et al. 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial. J Thorac Oncol. 2016;11:S115.
Suresh K, Voong KR, Shankar B, et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol. 2018;13:1930-1939.
Bala-Hampton JE, Bazzell AF, Dains JE. Clinical management of pneumonitis in patients receiving anti-PD-1/PD-L1 therapy. J Adv Pract Oncol. 2018;9:422-428.
Franzen D, Schad K, Kowalski B, et al. Ipilimumab and early signs of pulmonary toxicity in patients with metastastic melanoma: a prospective observational study. Cancer Immunol Immunother. 2018;67:127-134.
Guo Y, Tian X, Wang X, et al. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:1299-1299.
Zdanowicz MM. The pharmacology of immunosuppression. American journal of pharmaceutical education. 2009;73:144-144.
Remicade [package insert]. Horsham, PA: Janssen Biotech, Inc.; 2017.
Cellcept [package insert]. South San Franciso, CA: Genentech USA, Inc.; 2018.
Santini FC, Rizvi H, Plodkowski AJ, et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res. 2018;6:1093-1099.
Sandherr M, Hentrich M, von Lilienfeld-Toal M, et al. Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol. 2015;94:1441-1450.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Jared Weiss, MD

Associate Professor of Medicine
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Disclosures

Disclosure: Jared Weiss, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Celgene Corporation; EMD Serono, Inc.; G1 Therapeutics; Immunicum; Nanobiotix; Pfizer Inc.
Received grants for clinical research from: Celgene Corporation; Merck & Co., Inc.; Pfizer Inc.

Editors

Davecia R. Cameron, MS

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Davecia R. Cameron, MS, has disclosed no relevant financial relationships.

Christin Melton

Medical Writer

Disclosures

Disclosure: Christin Melton, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC, CHCP

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC / CE

Minimizing the Impact of imAEs and Maximizing Efficacy: Pulmonary Toxicity

Authors: Jared Weiss, MD
CME / ABIM MOC / CE Released: 3/25/2019
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 3/25/2020, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for pulmonologists, hematology/oncology specialists, emergency medicine physicians and nurses.

The goal of this activity is to educate members of the multidisciplinary and interprofessional cancer care team on recognizing and understanding how to manage immune-mediated adverse events (imAEs) related to the use of immune checkpoint inhibitors in the management of multiple cancers.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical trial data on imAEs due to treatment with immune checkpoint inhibitors
- Real-world evidence on the impact of steroids on the efficacy of immune checkpoint inhibitors in patients with cancer
Have greater competence related to
- Identifying strategies to maximize clinical outcomes in patients receiving immune checkpoint inhibitors
- Managing across the spectrum of severity of imAEs associated with immune checkpoint inhibitors
- Counseling patients on how to communicate with clinicians if they suspect an imAE

Disclosures

Faculty

Jared Weiss, MD

Associate Professor of Medicine
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Disclosures

Disclosure: Jared Weiss, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Celgene Corporation; EMD Serono, Inc.; G1 Therapeutics; Immunicum; Nanobiotix; Pfizer Inc.
Received grants for clinical research from: Celgene Corporation; Merck & Co., Inc.; Pfizer Inc.

Editors

Davecia R. Cameron, MS

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Davecia R. Cameron, MS, has disclosed no relevant financial relationships.

Christin Melton

Medical Writer

Disclosures

Disclosure: Christin Melton, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC, CHCP

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 1.25 contact hour(s) of continuing nursing education for RNs and APNs; 1.25 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Pulmonary Medicine

CME / ABIM MOC / CE

Minimizing the Impact of imAEs and Maximizing Efficacy: Pulmonary Toxicity

Authors: Jared Weiss, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 3/25/2019

Valid for credit through: 3/25/2020, 11:59 PM EST

processing....

PDF téléchargeable en français

Download the pdf.

Download Now

« Return to: Minimizing the Impact of imAEs and Maximizing Efficacy: Pulmonary Toxicity

PDF Downloads

Print
Like Tweet

References

Faculty and Disclosures

Faculty

Jared Weiss, MD

Editors

Davecia R. Cameron, MS

Christin Melton

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Minimizing the Impact of imAEs and Maximizing Efficacy: Pulmonary Toxicity

Target Audience and Goal Statement

Disclosures

Faculty

Jared Weiss, MD

Editors

Davecia R. Cameron, MS

Christin Melton

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Minimizing the Impact of imAEs and Maximizing Efficacy: Pulmonary Toxicity

PDF téléchargeable en français

PDF Downloads